IPAH(n = 96) | Distal CTEPH(n = 35) | Proximal CTEPH(n = 68) | p Value | |
---|---|---|---|---|
BMI, body mass index; BMPR2, bone morphogenetic protein receptor type II; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; IPAH, idiopathic pulmonary arterial hypertension; 6MWD, 6 min walking distance; TED, thromboembolic event. | ||||
Significant pairwise comparisons are listed below: | ||||
*p = 0.005 (IPAH vs proximal CTEPH); p = 0.002 (IPAH vs distal CTEPH). | ||||
†p<0.001 (IPAH vs proximal CTEPH); p = 0.04 (proximal CTEPH vs distal CTEPH). | ||||
‡p = 0.046 (IPAH vs proximal CTEPH); p = 0.046 (IPAH vs distal CTEPH). | ||||
§p<0.001 (IPAH vs proximal CTEPH); p<0.001 (IPAH vs distal CTEPH). | ||||
¶p<0.001 (IPAH vs proximal CTEPH); p<0.001 (IPAH vs distal CTEPH). | ||||
**p = 0.026 (proximal vs distal CTEPH). | ||||
Mean (SD) age (years)* | 46.2 (16.9) | 55.9 (13.1) | 54.8 (14.6) | <0.001 |
Male sex† | 29% | 43% | 69% | <0.001 |
Mean (SD) BMI (kg/m2) | 27.1 (5.8) | 27.9 (7.5) | 27.4 (3.9) | 0.77 |
Positive BMPR2 status‡ | 15% (n = 40) | 0% (n = 25) | 0% (n = 25) | 0.018 |
Prior TED§ | 5.2% | 74.3% | 75% | <0.001 |
Prior DVT¶ | 3.1% | 28.6% | 30.9% | <0.001 |
Previous splenectomy** | 3.1% | 11.4% | 1.6% | 0.042 |
Positive smoking history | 47.9% | 65.7% | 50% | 0.18 |
WHO functional class | ||||
II | 20 (21%) | 10 (29%) | 11 (16%) | |
III | 50 (53%) | 17 (49%) | 32 (47%) | |
IV | 24 (26%) | 8 (22%) | 25 (37%) | 0.37 |
Mean (SD) 6MWD (m) | 257 (118) | 254 (99) | 256 (131) | 1.00 |